INSMED INC's ticker is and the CUSIP is 457669AA7. A total of 38 filers reported holding INSMED INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $589,000 | -1.0% | 574,000 | 0.0% | 0.04% | -2.8% |
| Q3 2021 | $595,000 | -14.5% | 574,000 | -13.9% | 0.04% | -20.0% |
| Q2 2021 | $696,000 | -74.4% | 667,000 | -72.7% | 0.04% | -77.0% |
| Q1 2021 | $2,715,000 | -63.0% | 2,440,000 | -62.6% | 0.20% | -62.5% |
| Q4 2020 | $7,328,000 | +0.0% | 6,532,000 | -3.3% | 0.52% | -17.2% |
| Q3 2020 | $7,326,000 | +10.0% | 6,753,000 | -1.4% | 0.63% | +8.4% |
| Q2 2020 | $6,658,000 | +20.2% | 6,851,000 | +3.3% | 0.58% | +19.5% |
| Q1 2020 | $5,539,000 | -13.7% | 6,629,000 | -0.6% | 0.49% | +14.3% |
| Q4 2019 | $6,419,000 | +11.1% | 6,666,000 | -3.8% | 0.43% | +1.4% |
| Q3 2019 | $5,776,000 | -19.5% | 6,929,000 | -6.2% | 0.42% | -21.0% |
| Q2 2019 | $7,175,000 | +136.8% | 7,386,000 | +146.2% | 0.53% | +109.8% |
| Q1 2019 | $3,030,000 | -30.8% | 3,000,000 | -52.0% | 0.25% | -37.9% |
| Q4 2018 | $4,376,000 | -13.3% | 6,250,000 | +4.2% | 0.41% | +5.1% |
| Q3 2018 | $5,050,000 | -8.3% | 6,000,000 | 0.0% | 0.39% | -13.7% |
| Q2 2018 | $5,508,000 | +3.9% | 6,000,000 | 0.0% | 0.45% | +4.9% |
| Q1 2018 | $5,303,000 | – | 6,000,000 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 2,974,000 | $2,536,000 | 1.90% |
| Mohican Financial Management, LLC | 500,000 | $422,000 | 1.47% |
| LINDEN ADVISORS LP | 51,146,000 | $43,311,000 | 1.32% |
| ZAZOVE ASSOCIATES LLC | 15,101,000 | $12,810,000 | 1.11% |
| DLD Asset Management, LP | 24,500,000 | $20,911,000 | 1.03% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 31,749,000 | $26,863,000 | 0.55% |
| Cheyne Capital Management (UK) LLP | 1,000,000 | $853,000 | 0.51% |
| SSI INVESTMENT MANAGEMENT LLC | 6,000,000 | $5,050,000 | 0.39% |
| Jabre Capital Partners S.A. | 1,100,000 | $943,000 | 0.31% |
| Orbimed Advisors | 26,500,000 | $22,611,000 | 0.27% |